Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 10/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL582014 | 0.87 | NOTUM (0.43) | NOTUMDPP4HSD11B1 | |
| SCHEMBL586549 | 0.87 | FFAR2 (0.41) | NOTUMHSD11B1 | |
| SCHEMBL581326 | 0.87 | TP53 (0.41) | NOTUMSLC6A9HTTTP53ALDH1A1 | |
| SCHEMBL582163 | 0.85 | NOTUM (0.46) | NOTUMSLC6A9TACR1HSD11B1 | |
| SCHEMBL3075498 | 0.85 | NOTUM (0.37) | NOTUMDPP4DPP8DPP9DPP7 | |
| SCHEMBL587829 | 0.83 | DPP4 (0.38) | NOTUMSLC6A9HTTDPP4DPP8 | |
| Hydrochloric Acid SCHEMBL580918 | 0.82 | DPP4 (0.34) | SLC6A9DPP4DPP8DPP9DPP7 | |
| SCHEMBL586675 | 0.82 | FFAR4 (0.50) | NOTUMDPP4DPP8DPP7HSD11B1 | |
| SCHEMBL581665 | 0.81 | NOTUM (0.49) | NOTUMSLC6A9HSD11B1ALDH1A1 | |
| SCHEMBL28032451 | 0.81 | SLC6A9 (0.41) | SLC6A9TP53TACR1ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415378-B2 | Isoxazol-3(2H)-one analogs as therapeutic agents | ASTRAZENECA AB (SE) | 2013-04-09 | — | — | US | disclosed |
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261755-A1 | ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS | NR4A3, CBR3, OXER1 | NOTUM 2559/4885SLC6A9 1336/4885HTT 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.